The Use Status of Anticoagulation Drugs for Inpatients with Nonvalvular Atrial Fibrillation in Southwest China

Overview

Journal Int J Gen Med

Publisher Dove Medical Press

Specialty General Medicine

Date 2017 Mar 16

PMID 28293117

Citations 4

Authors

Huan Jie Zheng

Shu Kun Ouyang

Yue Zhao

Kai Lu

Su Xin Luo

Hua Xiao

Affiliations

Soon will be listed here.

Abstract

Background: Oral anticoagulants (OACs) are effective for the prophylaxis of stroke in patients with atrial fibrillation (AF). This cross-sectional study aimed to investigate the status of anticoagulation treatment for hospitalized AF patients in Southwest China.

Methods: A total of 4760 hospitalized patients with AF were enrolled from 21 hospitals in Chongqing city from January 1 to December 31, 2013.

Results: Among the enrolled patients, 3785 were diagnosed with nonvalvular AF. These patients had a mean age of 74.4±10.1 years. The mean CHADS score of all subjects was 2.60±1.34, and 80.7% of the patients had CHADS ≥2. The use rate of OACs was only 11.5% for patients with a high risk for stroke (CHADS ≥2) and was much lower in patients from the second-level hospitals than in patients from the third-level hospitals (5.8% vs. 16.9%, <0.001). The leading reason for the underuse of OACs in high-risk patients was physician's nonfeasance.

Conclusion: This study demonstrated that the underuse of anticoagulation therapy in hospitalized patients with nonvalvular AF was particularly serious in Southwest China, especially in the second-level hospitals. Urgent and effective measures are desperately needed to improve this alarming situation in China.

Citing Articles

Contemporary survival and anticoagulation of patients with atrial fibrillation: A community based cohort study in China.

Wei Y, Zeng Q, Cai L, Wang X, Wang B, Shen C Front Cardiovasc Med. 2022; 9:911393.

PMID: 35966522 PMC: 9363600. DOI: 10.3389/fcvm.2022.911393.

Left Atrial Thrombus in Patients With Non-valvular Atrial Fibrillation: A Cross-Sectional Study in China.

Shi S, Zhao Q, Liu T, Zhang S, Liang J, Tang Y Front Cardiovasc Med. 2022; 9:827101.

PMID: 35586655 PMC: 9109812. DOI: 10.3389/fcvm.2022.827101.

Antithrombotic strategy and its relationship with outcomes in patients with atrial fibrillation and chronic coronary syndrome.

Lv W, Dong J, Du X, Hu R, He L, Long D J Thromb Thrombolysis. 2021; 53(4):868-877.

PMID: 34677727 DOI: 10.1007/s11239-021-02588-z.

The use of anticoagulants in patients with non-valvular atrial fibrillation between 2005 and 2014: A drug utilization study using claims data in Japan.

Kubota K, Ooba N, Kamijima Y, Sato K, Koide D PLoS One. 2018; 13(9):e0203380.

PMID: 30183755 PMC: 6124773. DOI: 10.1371/journal.pone.0203380.

References

van Walraven C, Hart R, Singer D, Laupacis A, Connolly S, Petersen P . Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA. 2002; 288(19):2441-8. DOI: 10.1001/jama.288.19.2441. View

Akao M, Chun Y, Wada H, Esato M, Hashimoto T, Abe M . Current status of clinical background of patients with atrial fibrillation in a community-based survey: the Fushimi AF Registry. J Cardiol. 2013; 61(4):260-6. DOI: 10.1016/j.jjcc.2012.12.002. View

Wolf P, DAWBER T, THOMAS Jr H, Kannel W . Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology. 1978; 28(10):973-7. DOI: 10.1212/wnl.28.10.973. View

Kirchhof P, Ammentorp B, Darius H, De Caterina R, Le Heuzey J, Schilling R . Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events--European Registry in Atrial Fibrillation (PREFER in AF). Europace. 2013; 16(1):6-14. PMC: 3864758. DOI: 10.1093/europace/eut263. View

Hart R, Pearce L, Aguilar M . Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146(12):857-67. DOI: 10.7326/0003-4819-146-12-200706190-00007. View

Zhou Z, Hu D, Chen J, Zhang R, Li K, Zhao X . [An epidemiological survey of atrial fibrillation in China]. Zhonghua Nei Ke Za Zhi. 2004; 43(7):491-4. View

Miller N . Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med. 1997; 102(2A):43-9. DOI: 10.1016/s0002-9343(97)00467-1. View

Waldo A, Becker R, Tapson V, Colgan K . Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol. 2005; 46(9):1729-36. DOI: 10.1016/j.jacc.2005.06.077. View

Wang Y, Cui L, Ji X, Dong Q, Zeng J, Wang Y . The China National Stroke Registry for patients with acute cerebrovascular events: design, rationale, and baseline patient characteristics. Int J Stroke. 2011; 6(4):355-61. DOI: 10.1111/j.1747-4949.2011.00584.x. View

10.

Choudhry N, Anderson G, Laupacis A, Ross-Degnan D, Normand S, Soumerai S . Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis. BMJ. 2006; 332(7534):141-5. PMC: 1336760. DOI: 10.1136/bmj.38698.709572.55. View

11.

Sun Y, Hu D . [Chinese subgroup analysis of the global anticoagulant registry in the FIELD (GARFIELD) registry in the patients with non-valvular atrial fibrillation]. Zhonghua Xin Xue Guan Bing Za Zhi. 2015; 42(10):846-50. View

12.

Liu B, Liu L, Xuan J, Luo M, Li Y, Duan C . Treatment patterns associated with stroke prevention in patients with atrial fibrillation in three major cities in the People's Republic of china. Int J Gen Med. 2014; 7:29-35. PMC: 3872083. DOI: 10.2147/IJGM.S49477. View

13.

Wen-Hang Q . Retrospective investigation of hospitalised patients with atrial fibrillation in mainland China. Int J Cardiol. 2005; 105(3):283-7. DOI: 10.1016/j.ijcard.2004.12.042. View

14.

Kagansky N, Knobler H, Rimon E, Ozer Z, Levy S . Safety of anticoagulation therapy in well-informed older patients. Arch Intern Med. 2004; 164(18):2044-50. DOI: 10.1001/archinte.164.18.2044. View

15.

Kimmel S, Chen Z, Price M, Parker C, Metlay J, Christie J . The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. Arch Intern Med. 2007; 167(3):229-35. DOI: 10.1001/archinte.167.3.229. View

16.

van Walraven C, Hart R, Connolly S, Austin P, Mant J, Hobbs F . Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke. 2009; 40(4):1410-6. DOI: 10.1161/STROKEAHA.108.526988. View

17.

Fuster V, Ryden L, Cannom D, Crijns H, Curtis A, Ellenbogen K . 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice.... J Am Coll Cardiol. 2011; 57(11):e101-98. DOI: 10.1016/j.jacc.2010.09.013. View

18.

Nieuwlaat R, Capucci A, Camm A, Bertil Olsson S, Andresen D, Davies D . Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005; 26(22):2422-34. DOI: 10.1093/eurheartj/ehi505. View

19.

Mant J, Hobbs F, Fletcher K, Roalfe A, Fitzmaurice D, Lip G . Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007; 370(9586):493-503. DOI: 10.1016/S0140-6736(07)61233-1. View

20.

Lane D, Ponsford J, Shelley A, Sirpal A, Lip G . Patient knowledge and perceptions of atrial fibrillation and anticoagulant therapy: effects of an educational intervention programme. The West Birmingham Atrial Fibrillation Project. Int J Cardiol. 2005; 110(3):354-8. DOI: 10.1016/j.ijcard.2005.07.031. View